A. Bols MD, PhD, K. Geboes MD, PhD, M. De Man MD, T. Delaunoit MD, I. Sinapi MD, J. Carrasco MD, PhD, M. Peeters MD, PhD
A retrospective study in patients treated with aflibercept plus FOLFIRI in second line for metastatic colorectal cancer (mCRC) was conducted in Belgium. A total of 102 patients (64.7% males; 62.9 ± 9.8 [mean ± SD] years-old; 36.3% Eastern Cooperative Oncology Group [ECOG] 0 and 63.7% ECOG 1 status) were included. At the end of the study, 47.1% of patients were deceased and 49% were still alive. The median overall survival (± SD) was 15.7 ±1.2 months (no statistically significant difference [p=0.706; log rank test] in survival as a function of the ECOG status). The median progression-free survival was 7.1 ±1.0 months (no statistically significant difference [p=0.732; log rank test] in progression-free survival as a function of the ECOG status). Aflibercept treatment was still ongoing in 22.5% of the patients. The treatment was stopped in 79 (77.5%) patients. In 16 patients (15.7%), treatment with aflibercept was discontinued due to drug toxicity. The average aflibercept treatment duration was 4.5 ± 4.5 months and the average number of aflibercept administrations was 8.7 ± 6.7. Overall, 62% of the patients having interrupted aflibercept received at least one targeted therapy or one chemotherapy after aflibercept. The three most frequent targeted therapies were regorafenib (46%), panitumumab (30%) and cetuximab (18%). The four most frequent chemotherapies were FOLFIRI (44.7%), FOLFOX (12.8%), irinotecan (12.8%) and capecitabine (12.8%). The results obtained using a retrospective observational real-life setting in Belgium globally corroborate those observed in the VELOUR randomised placebo-controlled trial.